What Researchers Did
This study investigated the clinical, biochemical, and imaging factors that influenced the decision to use hyperbaric oxygen therapy (HBOT) for patients with carbon monoxide poisoning.
What They Found
Out of 272 adult patients with carbon monoxide poisoning, 103 patients (37.9%) received HBOT, while 169 patients (62.1%) received normobaric oxygen therapy. Patients selected for HBOT had significantly lower Glasgow Coma Scale scores, higher cardiac biomarkers, and more frequent signs of heart ischemia on their electrocardiograms. Lower Glasgow Coma Scale scores, ischemic ECG findings, and lactate levels were independently linked to the choice of HBOT.
Canadian Relevance
This study covers carbon monoxide poisoning, which is a Health Canada-recognized indication for hyperbaric oxygen therapy.
Study Limitations
As a retrospective cohort study, it relied on existing patient data, which may have inherent limitations in data collection and completeness.